To improve our understanding of the role of STAT5 in enzalutamide resistance, we evaluated its role in cell models and assessed its value as a potential therapeutic target in enzalutamide-resistant PCa in vitro. The gene discussed is STAT5A; the disease is posterior cortical atrophy.